Christophe Willekens

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea et al. · Blood · 2017 · 1.4K citations · Full text

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Aymeric Silvin, Nicolas Chapuis, Garett Dunsmore et al. · Cell · 2020 · 898 citations · Full text

Mild Covid-19, Hematological Malignancy, Hematology +5

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia

Tamara Maes, Cristina Mascaró, Iñigo Tirapu et al. · Cancer Cell · 2018 · 326 citations · Full text

Hematological Malignancy, Medicine, Drug Discovery +8

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Dorothée Selimoglu‐Buet, Orianne Wagner‐Ballon, Véronique Saada et al. · Blood · 2015 · 249 citations